{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:57:49Z","timestamp":1793923069488,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019832","name":"Gal\u00e1pagos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.autrev.2023.103504","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T21:38:08Z","timestamp":1703021888000},"page":"103504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study"],"prefix":"10.1016","volume":"23","author":[{"given":"Virginia","family":"Solitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Facheris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo A.","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"D'Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Chary-Valckenaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Felten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Gustavo","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Erik","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent Peyrin","family":"Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103504_bb0005","first-page":"1768","article-title":"Cardiovascular and Cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"Reply N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103504_bb0010","first-page":"201","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with Baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.autrev.2023.103504_bb0020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/1389450121666200902164240","article-title":"Thrombosis in IBD in the Era of JAK inhibition","volume":"22","author":"Solitano","year":"2021","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.autrev.2023.103504_bb0025","first-page":"6","article-title":"Dermatologic applications and safety considerations of Janus kinase inhibitors","volume":"25","author":"Svoboda","year":"2020","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.autrev.2023.103504_bb0030","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s10067-022-06471-x","article-title":"JAK inhibitors, cardiovascular and thromboembolic events: what we know and what we would like to know","volume":"42","author":"Evangelatos","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103504_bb0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41575-022-00722-7","article-title":"Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance","volume":"20","author":"Danese","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2023.103504_bb0040","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40264-023-01333-0","article-title":"Managing cardiovascular and cancer risk associated with JAK inhibitors","volume":"46","author":"Yang","year":"2023","journal-title":"Drug Saf"},{"key":"10.1016\/j.autrev.2023.103504_bb0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2023.103504_bb0050","article-title":"Start RA treatment - biologics or JAK-inhibitors?","author":"Caporali","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103504_bb0055","article-title":"The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort","author":"Tomelleri","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103504_bb0060","series-title":"The RAND\/UCLA appropriateness method User\u2019s manual","author":"Fitch","year":"2001"},{"key":"10.1016\/j.autrev.2023.103504_bb0065","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2023.103504_bb0070","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103504_bb0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjcard.2012.03.026","article-title":"Cardiologist concordance with the American College of Cardiology appropriate use criteria for cardiac testing in patients with coronary artery disease","volume":"110","author":"Lin","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.autrev.2023.103504_bb0080","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0964-3397(98)80614-9","article-title":"Determining patients' suitability for thrombolysis: coronary care nurses' agreement with an expert cardiological 'gold standard' as assessed by clinical and electrocardiographic 'vignettes'","volume":"14","author":"Quinn","year":"1998","journal-title":"Intensive Crit Care Nurs"},{"key":"10.1016\/j.autrev.2023.103504_bb0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.apmr.2022.08.002","article-title":"Using clinical vignettes and a modified expert Delphi panel to determine parameters for identifying non-traumatic spinal cord injury in health administrative and electronic medical record databases","volume":"104","author":"Senthinathan","year":"2023","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.autrev.2023.103504_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09638288.2023.2265820","article-title":"Tailoring of exercise and dietary interventions to adverse effects and existing comorbidities in patients with ovarian cancer receiving chemotherapy: a clinical vignettes study among expert physical therapists and dietitians","author":"Stelten","year":"2023","journal-title":"Disabil Rehabil"},{"key":"10.1016\/j.autrev.2023.103504_bb0095","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12931-021-01737-5","article-title":"An updated overview of e-cigarette impact on human health","volume":"22","author":"Marques","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.autrev.2023.103504_bb0100","first-page":"9","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2023.103504_bb0105","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","article-title":"Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts","volume":"78","author":"Boel","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103504_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/S1590-8658(23)00429-2","article-title":"Safety and effectiveness of tofacitinib in ulcerative colitis: data from TOFA-UC, a SN-IBD study","author":"Macaluso","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2023.103504_bb0115","doi-asserted-by":"crossref","first-page":"861","DOI":"10.14309\/ajg.0000000000002129","article-title":"REMIT-UC: real-world effectiveness and safety of Tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD research consortium multicenter National Cohort Study","volume":"118","author":"Ma","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2023.103504_bb0120","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.cgh.2020.10.025","article-title":"Real-world effectiveness and safety of Tofacitinib in Crohn\u2019s disease and IBD-U: a multicenter study from the TROPIC consortium","volume":"19","author":"Fenster","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2023.103504_bb0125","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","article-title":"Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme","volume":"17","author":"Sandborn","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2023.103504_bb0130","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad100","article-title":"Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis","author":"Solitano","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2023.103504_bb0135","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2023.103504_bb0140","article-title":"Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: a 52-week retrospective study","author":"Gargiulo","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2023.103504_bb0145","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40268-022-00396-1","article-title":"Effectiveness and safety of Upadacitinib in the treatment of moderate-severe atopic dermatitis: a multicentric, prospective, real-world, cohort study","volume":"22","author":"Chiricozzi","year":"2022","journal-title":"Drugs R D"},{"key":"10.1016\/j.autrev.2023.103504_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15636","article-title":"Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis","volume":"35","author":"Wan","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2023.103504_bb0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103504_bb0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103504_bb0165","series-title":"EULAR recommendations for the management of psoriatic arthritis: 2023 update","author":"Gossec","year":"2023"},{"key":"10.1016\/j.autrev.2023.103504_bb0170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103504_bb0175","first-page":"6","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2023.103504_bb0180","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.2023-0145","article-title":"Safety of Janus kinase inhibitors: a real-world multicenter retrospective cohort study","author":"Lanzillotta","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103504_bb0185","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223002380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223002380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T02:29:24Z","timestamp":1715048964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223002380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1568997223002380"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103504","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103504"}}